REX Files for REX Peptides ETF Targeting the Growing Peptide Market
On July 27, REX Shares filed to launch the REX Peptides ETF (ticker not yet assigned), which will track the VettaFi Peptides Index. The fund aims to provide exposure across the entire peptide value chain by investing in companies involved in drug development, infrastructure, oral delivery solutions, and cosmeceuticals. This follows a surge of interest driven largely by GLP-1 weight loss medications, whose adoption among U.S. adults increased from 3% in 2024 to 11% in 2026. The ETF’s index includes companies with at least $100 million market cap and $1 million average daily trading volume. It divides holdings into two tranches—core (80%) for pure-play peptide firms, and diversified (20%) for broader industry participants—with strict caps on concentration risk to ensure balanced exposure. The growing GLP-1 demand has led to global supply shortages and spurred significant investment in manufacturing infrastructure. Additionally, a recent FDA advisory committee recommendation may pave the way for regulated production of wellness peptides by compounding pharmacies, potentially shifting this market from unregulated grey areas into mainstream acceptance.
Tickers: $MS
Topics: biotech investment ETFs peptides